In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI identifies ...
In a statement sent to Pharmaceutical Executive, AMCP CEO Susan A. Cantrell, MHL, RPh, CAE, said, “Although President Trump’s ...
The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone against the current standard-of-care in patients with ...
In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI compares ...
The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...
Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sumao ...
The FDA has approved an expanded label for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which ...
A Harvard Business School Healthcare Alumni Association Q&A with Spencer Stuart’s Claudius A. Hildebrand.
Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...
Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.
President Trump’s tariffs will include imported pharmaceuticals, among other items that will impact the industry.
Future development plans include incorporating AI, expanding connectors, and specializing in additional therapeutic areas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback